The clinical efficacy of metacycline and rifampicin in patients with intractable Brucellosis
10.3760/cma.j.issn.2095-4255.2018.01.016
- VernacularTitle:美他环素联合利福平治疗难治性布鲁菌病的临床疗效观察
- Author:
Wanpeng WANG
1
;
Bingqin TAN
;
Zhenwu YAN
;
Ting XIAO
;
Jianhong CHEN
Author Information
1. 山东省潍坊市人民医院感染性疾病科
- Keywords:
Metacycline;
Rifampicin;
Brucellosis;
Clinical efficacy
- From:
Chinese Journal of Endemiology
2018;37(1):73-76
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the clinical efficacy of metacycline and rifampicin in the patients with refractory brucellosis,and to provide evidence for clinical treatment.Methods From February 2013 to February 2016,sixty-five patients diagnosed refractory brucellosis at the Department of Infectious Diseases,Weifang People's Hospital were enrolled in this study.They were randomly divided into two groups,treatment group (33 cases) and control group (32 cases).Patients of treatment group were treated with metacycline joint rifampicin,and control group was treated with doxycycline hyclate,rifampicin and levofloxacin.After treatment for six weeks,the clinical efficacy and adverse reactions were observed and data were analyzed.Results The effective rate in treatment group (96.97％,32/33) was significantly higher than that in control group (75.00％,24/32,x2 =4.86,P ＜ 0.05).The incidence of gastrointestinal reactions in control group (37.50％,12/32) was much higher than that in treatment group (15.15％,5/33,x2 =4.20,P ＜ 0.05).There were no significant differences between the two groups in the incidence of liver damage,skin rash and leukopenia (x2 =0.49,0.00,1.62,P ＞ 0.05).Conclusion The combined treatment metacycline and rifampicin is safe with high efficiency for patients with refractory brucellosis,and is worthy to be promoted.
